Warner Chilcott: Revenues fell 6.8% year on year

Warner Chilcott Plc (NASDAQ:WCRX). Last Market Price: 17.01, Change: -1.36, % Change: (-7.40%). Shares trade in the range of 16.17 – 18.21 dollars. It has a market capitalization of 4.32B dollars, making it a Mid Cap Stock and has 254.08M outstanding shares. The company has a beta of 1.15, indicating, the stock to be more volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is 0.47; P/E of 35.99 indicating high expected future growth in earnings. It operates in Healthcare sector and belongs to Biotechnology and Drugs industry. The company has a 52 week Price range (low – high) of $ 12.90 – 25.92. Average volumes of shares traded daily are 2,400,000. Volume traded in the last session was at 5,040,000, 2.10 times the average volume.

• Reports Q3 (Sep)
• EPS of $0.89, worse than the estimates
• Revenues fell 6.8% year on year to $655.5 million

• Company reaffirms guidance for FY11, sees EPS of $3.70-3.80

• Company States: Based on our third quarter results and current outlook for the remainder of 2011, we are reaffirming our guidance ranges for total revenue, adjusted gross margin as a percentage of total revenue, total SG&A expense, GAAP net income, adjusted CNI and adjusted CNI per share for the full year 2011. We are lowering our expectations for total R&D expense from a range of $120 million to $140 million, to a range of $110 million to $130 million, due primarily to changes in the expected timing of expenses with respect to projects under development. We are adjusting our expectations for the total income tax guidance from a range of 10% to 11% to a range of 11% to 12%. This increase is based primarily on the impact of the Western European restructuring, changes in the jurisdictional mix of income and an anticipated increase in non-deductible expenses

For Q2 (Jun ’11), It had a Net profit margin of 10.72%, an Operating margin of 13.89%. Other Key stats and ratios are : Return on average assets of 5.65%. The organization has an employee strength of 2,700

Consensus Recommendation is a Outperform.

Estimate for sales for the Year Ending Dec-11 show a mean of 2,741.80 million dollars, an estimate high of 2,783.00 million dollars and an estimate low of 2,720.00 million dollars. A year ago the figures stood at 3,027.20 million dollars.

Estimate for sales for the Year Ending Dec-12 show a mean of 2,744.84 million dollars, an estimate high of 2,954.20 million dollars and an estimate low of 2,658.50 million dollars. A year ago the figures stood at 3,069.58 million dollars.

Estimate for EPS for the Year Ending Dec-11 show a mean of 3.78 dollars, an estimate high of 3.87 dollars and an estimate low of 3.70 dollars. A year ago the figures stood at 3.53 dollars.

Estimate for EPS for the Year Ending Dec-12 show a mean of 4.06 dollars, an estimate high of 4.37 dollars and an estimate low of 3.80 dollars. A year ago the figures stood at 3.90 dollars.

Sales for Quarter Ending Sep-11 was estimated at 655.37 million dollars, however the actual sales figure stood at 655.46 million dollars, 0.1 million dollars more than estimates.

Sales for Quarter Ending Jun-11 was estimated at 675.51 million dollars, however the actual sales figure stood at 670.29 million dollars, 5.21 million dollars less than estimates.

Post Written By: Ed Liston Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.